Humoral and cellular immune responses after 6 months of a heterologous SARS-CoV-2 booster with the protein-based PHH-1V vaccine in a phase IIb trial

Author:

Corominas Júlia,Garriga Carme,Prenafeta Antoni,Moros Alexandra,Cañete Manuel,Barreiro Antonio,González-González Luis,Madrenas Laia,Güell Irina,Clotet Bonaventura,Izquierdo-Useros Nuria,Raïch-Regué Dàlia,Gallemí Marçal,Blanco Julià,Pradenas Edwards,Trinité Benjamin,Prado Julia G,Pérez-Caballero Raúl,Bernad Laia,Plana Montserrat,Esteban Ignasi,Aurrecoechea Elena,Taleb Rachel Abu,McSkimming Paula,Soriano Alex,Nava Jocelyn,Anagua Jesse Omar,Ramos Rafel,Lluch Ruth Martí,Comes Aida Corpes,Romero Susana Otero,Martínez-Gómez Xavier,Camacho-Arteaga Lina,Molto Jose,Benet Susana,Bailón Lucía,Arribas Jose R,Borobia Alberto M,Parada Javier Queiruga,Navarro-Pérez Jorge,Giner Maria José Forner,Lucas Rafael Ortí,Jiménez María del Mar Vázquez,Fernández María Jesús López,Alvarez-Mon Melchor,Troncoso Daniel,Arana-Arri Eunate,Meijide Susana,Imaz-Ayo Natale,García Patricia Muñoz,de la Villa Sofía,Fernández Sara Rodríguez,Prat Teresa,Torroella Èlia,Ferrer Laura

Abstract

SummaryThe HIPRA-HH-2 was a multicentre, randomized, active-controlled, double-blind, non-inferiority phase IIb clinical trial to compare the immunogenicity and safety of a heterologous booster with PHH-1V adjuvanted recombinant vaccine versus a homologous booster with mRNA vaccine. Interim results showed a strong humoral and cellular immune response against the SARS-CoV-2 Wuhan-Hu-1 strain and the Beta, Delta, and Omicron BA.1 variants up to day 98 after dosing. Here we report that these humoral and cellular responses after PHH-1V dosing are sustained up to 6 months. These results are observed both when including or not participants who reported SARS-CoV-2 infection and in a high-risk population (≥65 years). Additional analysis revealed a non-inferiority of PHH-1V booster in eliciting neutralizing antibodies also for SARS-CoV-2 Omicron XBB.1.5 when compared to mRNA vaccine after 6 months. The PHH-1V vaccine provides long-lasting protection against a wide variety of SARS-CoV-2 emerging variants to prevent severe COVID-19.ClinicalTrials.govIdentifierNCT05142553

Publisher

Cold Spring Harbor Laboratory

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3